BlackRock’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-170,945
| Closed | -$47K | – | 5952 |
|
|
2022
Q3 | $47K | Sell |
170,945
-3,509
| -2% | -$1.39K | ﹤0.01% | 5376 |
|
|
2022
Q2 | $61K | Sell |
174,454
-41,662
| -19% | -$21.1K | ﹤0.01% | 5375 |
|
|
2022
Q1 | $146K | Sell |
216,116
-2,493
| -1% | -$2.73K | ﹤0.01% | 5194 |
|
|
2021
Q4 | $506K | Buy |
218,609
+2,873
| +1% | +$9.72K | ﹤0.01% | 4869 |
|
|
2021
Q3 | $988K | Sell |
215,736
-5,412
| -2% | -$23.8K | ﹤0.01% | 4561 |
|
|
2021
Q2 | $982K | Sell |
221,148
-762,863
| -78% | -$3.88M | ﹤0.01% | 4525 |
|
|
2021
Q1 | $7.16M | Buy |
984,011
+80,284
| +9% | +$661K | ﹤0.01% | 3763 |
|
|
2020
Q4 | $6.89M | Buy |
903,727
+183,768
| +26% | +$1.23M | ﹤0.01% | 3557 |
|
|
2020
Q3 | $6.54M | Buy |
719,959
+21,592
| +3% | +$164K | ﹤0.01% | 3458 |
|
|
2020
Q2 | $5.91M | Buy |
698,367
+200,218
| +40% | +$1.32M | ﹤0.01% | 3457 |
|
|
2020
Q1 | $2.46M | Sell |
498,149
-7,131
| -1% | -$55.5K | ﹤0.01% | 3594 |
|
|
2019
Q4 | $3.64M | Buy |
505,280
+38,159
| +8% | +$345K | ﹤0.01% | 3590 |
|
|
2019
Q3 | $5.05M | Buy |
467,121
+15,398
| +3% | +$165K | ﹤0.01% | 3480 |
|
|
2019
Q2 | $5.87M | Buy |
451,723
+85,079
| +23% | +$1.13M | ﹤0.01% | 3485 |
|
|
2019
Q1 | $3.62M | Sell |
366,644
-10,910
| -3% | -$102K | ﹤0.01% | 3522 |
|
|
2018
Q4 | $3.93M | Buy |
+377,554
| New | +$4.56M | ﹤0.01% | 3478 |
|
BlackRock's LOGC Position: Q4 2022 in Review
BlackRock sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 170,945 shares — an estimated $47K sold.
BlackRock first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $7.16M in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- BlackRock reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- BlackRock sold 170,945 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $47K.
- BlackRock first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- BlackRock's LogicBio Therapeutics, Inc. Common Stock position peaked at $7.16M in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.